A New Therapeutic Option for BCG-Unresponsive Bladder Cancer

An immune-cell–activating interleukin-15 superagonist led to a complete response in 71% of patients.

Patients with high-grade T1 or carcinoma in situ (CIS) bladder cancer who are unresponsive to treatment with intravesical bacillus Calmette–Guérin (BCG) have limited management options.

Now, investigators have conducted an industry-sponsored, multicenter, three-cohort, open-label trial to determine if intravesical nogapendekin alfa inbakicept (NAI) — an immune-cell–

activating interleukin-15 superagonist — can act synergistically with BCG in patients with BCG-unresponsive, non–muscle-invasive bladder cancer (NMIBC).

Patients in the three cohorts were treated for 6 weeks with the following results:

Cohort A (84 patients), with BCG-unresponsive CIS with or without Ta/T1 papillary NMIBC, received NAI plus BCG. At median follow-up of 23.9 months, t…

Reviewing Author

Robert Dreicer, MD, MS, MACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Robert Dreicer, MD, MS, MACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

A New Therapeutic Option for BCG-Unresponsive Bladder Cancer

Topics

Reviewing Author